Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4387-4393

  Sasako, Mitsuru ^a   Sakuramoto, Shinichi ^b   Katai, Hitoshi ^c   Kinoshita, Taira ^g   Furukawa, Hiroshi ^h   Yamaguchi, Toshiharu ^d   Nashimoto, Atsushi ⁱ   Fujii, Masashi ^e   Nakajima, Toshifusa ^d   Ohashi, Yasuo ^f  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h SAKAI MUNICIPAL HOSPITAL   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; DEMOGRAPHY; DISEASE FREE SURVIVAL; FOLLOW UP; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHADENECTOMY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; GASTRECTOMY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR;

EID: 81755171104     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.5908     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, et al.: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, 2010. http://www.iarc.fr/en/publications/ eresources/cancerbases/index.php
2. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993 (Pubitemid 23228247)
3. Piedbois P, Buyse M: Meta-analyses need time, collaboration, and funding. J Clin Oncol 12:878-880, 1994
4. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non- Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 35:1059-1064, 1999
5. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials-A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11:837-843, 2000
6. Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88:21-27, 2002 (Pubitemid 34269794)
7. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: A metaanalysis. JAMA 303:1729-1737, 2010
8. Shirasaka T, Shimamato Y, Ohshimo H, et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557, 1996 (Pubitemid 26276346)
9. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park) 13:17-21, 1999
10. Sakata Y, Ohtsu A, Horikoshi N, et al.: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720, 1998 (Pubitemid 28474225)
11. Koizumi W, Kurihara M, Nakano S, et al.: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer: For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-197, 2000 (Pubitemid 30189900)
12. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007 (Pubitemid 350044801)
13. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1:10-24, 1998
14. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
15. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
16. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908-914, 1999 (Pubitemid 29141051)
17. Bunt AM, Hermans J, Smit VT, et al.: Surgical/ pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13:19-25, 1995
18. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345:745-748, 1995
19. Songun I, Putter H, Kranenbarg EM, et al.: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449, 2010
20. Okines A, Verheij M, Allum W, et al.: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v50-v54, 2010
21. Cunningham D, Chua YJ: East meets West in the treatment of gastric cancer. N Engl J Med 357:1863-1865, 2007 (Pubitemid 350044810)
22. Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9:215-221, 2008
23. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006 (Pubitemid 46631401)
24. Ajani JA, Moiseyenko VM, Tjulandin S, et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 25: 3210-3216, 2007 (Pubitemid 47325603)
25. Fujitani K, Tamura S, Kimura Y, et al.: Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604). J Clin Oncol 27, 2009 (suppl; abstr e15567)
26. Takahari D, Hamaguchi T, Yoshimura K, et al.: Feasibility study of adjuvant chemothe rapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 67:1423-1428, 2011
27. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010